Aktiesnakken — August 2017
-
Celgene hæver bundlinjen med 77 pct.
Amerikanske Celgene har i andet kvartal lagt hele 77 pct. til sit nettoresultat. Det skyldes primært gedigen vækst for knoglemarvskræftmidlet Revlimid, der er en rival til Genmabs Darzalex.
(medwatch.dk)
-
Tak sukker.
-
God morgen.
-
Enig, hvad har lige ændret sig!
-
God morgen.
-
Pandora: Det var da noget af et fald i går. AB nettosælger 1.23 mio stk. LPC har endog nedbragt shorts med 0.05% (total short nu 5.75%), men kan være andre, der har sat nye? Var det ikke lidt overreageret? - ledelsen fastholder jo sine forventninger.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind